Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amg 224
- Development stage
- Phase 1
- Lead developer
- Amgen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMG 224 is an investigational antibody-drug conjugate (ADC) developed for the treatment of multiple myeloma. It consists of an anti-human B-cell maturation antigen (BCMA) IgG1 antibody conjugated to mertansine (DM1), a cytotoxic maytansinoid, via a non-cleavable linker. The drug is designed to target BCMA-expressing malignant plasma cells, delivering the cytotoxic agent directly to these cells and inhibiting microtubule assembly, which leads to cell death. Clinical studies have evaluated its safety and efficacy in patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy[5][6][7].
- Other names
- AMG 224AMG224AMG-224
02
Targets
TUBB (Tubulin (alpha and beta subunits))BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on amg 224.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amg 224.